Cargando…

Therapeutic manipulation of angiogenesis with miR-27b

BACKGROUND: Multiple studies demonstrated pro-angiogenic effects of microRNA (miR)-27b. Its targets include Notch ligand Dll4, Sprouty (Spry)-2, PPARγ and Semaphorin (SEMA) 6A. miR-27 effects in the heart are context-dependent: although it is necessary for ventricular maturation, targeted overexpres...

Descripción completa

Detalles Bibliográficos
Autores principales: Veliceasa, Dorina, Biyashev, Dauren, Qin, Gangjian, Misener, Sol, Mackie, Alexander Roy, Kishore, Raj, Volpert, Olga V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497374/
https://www.ncbi.nlm.nih.gov/pubmed/26161255
http://dx.doi.org/10.1186/s13221-015-0031-1
_version_ 1782380504930058240
author Veliceasa, Dorina
Biyashev, Dauren
Qin, Gangjian
Misener, Sol
Mackie, Alexander Roy
Kishore, Raj
Volpert, Olga V.
author_facet Veliceasa, Dorina
Biyashev, Dauren
Qin, Gangjian
Misener, Sol
Mackie, Alexander Roy
Kishore, Raj
Volpert, Olga V.
author_sort Veliceasa, Dorina
collection PubMed
description BACKGROUND: Multiple studies demonstrated pro-angiogenic effects of microRNA (miR)-27b. Its targets include Notch ligand Dll4, Sprouty (Spry)-2, PPARγ and Semaphorin (SEMA) 6A. miR-27 effects in the heart are context-dependent: although it is necessary for ventricular maturation, targeted overexpression in cardiomyocytes causes hypertrophy and dysfunction during development. Despite significant recent advances, therapeutic potential of miR-27b in cardiovascular disease and its effects in adult heart remain unexplored. Here, we assessed the therapeutic potential of miR-27b mimics and inhibitors in rodent models of ischemic disease and cancer. METHODS: We have used a number of models to demonstrate the effects of miR-27b mimicry and inhibition in vivo, including subcutaneous Matrigel plug assay, mouse models of hind limb ischemia and myocardial infarction and subcutaneous Lewis Lung carcinoma. RESULTS: Using mouse model of myocardial infarction due to the coronary artery ligation, we showed that miR-27b mimic had overall beneficial effects, including increased vascularization, decreased fibrosis and increased ejection fraction. In mouse model of critical limb ischemia, miR-27b mimic also improved tissue re-vascularization and perfusion. In both models, miR-27b mimic clearly decreased macrophage recruitment to the site of hypoxic injury. In contrast, miR-27b increased the recruitment of bone marrow derived cells to the neovasculature, as was shown using mice reconstituted with fluorescence-tagged bone marrow. These effects were due, at least in part, to the decreased expression of Dll4, PPARγ and IL10. In contrast, blocking miR-27b significantly decreased vascularization and reduced growth of subcutaneous tumors and decreased BMDCs recruitment to the tumor vasculature. CONCLUSIONS: Our study demonstrates the utility of manipulating miR-27b levels in the treatment of cardiovascular disease and cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13221-015-0031-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4497374
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44973742015-07-10 Therapeutic manipulation of angiogenesis with miR-27b Veliceasa, Dorina Biyashev, Dauren Qin, Gangjian Misener, Sol Mackie, Alexander Roy Kishore, Raj Volpert, Olga V. Vasc Cell Research BACKGROUND: Multiple studies demonstrated pro-angiogenic effects of microRNA (miR)-27b. Its targets include Notch ligand Dll4, Sprouty (Spry)-2, PPARγ and Semaphorin (SEMA) 6A. miR-27 effects in the heart are context-dependent: although it is necessary for ventricular maturation, targeted overexpression in cardiomyocytes causes hypertrophy and dysfunction during development. Despite significant recent advances, therapeutic potential of miR-27b in cardiovascular disease and its effects in adult heart remain unexplored. Here, we assessed the therapeutic potential of miR-27b mimics and inhibitors in rodent models of ischemic disease and cancer. METHODS: We have used a number of models to demonstrate the effects of miR-27b mimicry and inhibition in vivo, including subcutaneous Matrigel plug assay, mouse models of hind limb ischemia and myocardial infarction and subcutaneous Lewis Lung carcinoma. RESULTS: Using mouse model of myocardial infarction due to the coronary artery ligation, we showed that miR-27b mimic had overall beneficial effects, including increased vascularization, decreased fibrosis and increased ejection fraction. In mouse model of critical limb ischemia, miR-27b mimic also improved tissue re-vascularization and perfusion. In both models, miR-27b mimic clearly decreased macrophage recruitment to the site of hypoxic injury. In contrast, miR-27b increased the recruitment of bone marrow derived cells to the neovasculature, as was shown using mice reconstituted with fluorescence-tagged bone marrow. These effects were due, at least in part, to the decreased expression of Dll4, PPARγ and IL10. In contrast, blocking miR-27b significantly decreased vascularization and reduced growth of subcutaneous tumors and decreased BMDCs recruitment to the tumor vasculature. CONCLUSIONS: Our study demonstrates the utility of manipulating miR-27b levels in the treatment of cardiovascular disease and cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13221-015-0031-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-24 /pmc/articles/PMC4497374/ /pubmed/26161255 http://dx.doi.org/10.1186/s13221-015-0031-1 Text en © Veliceasa et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Veliceasa, Dorina
Biyashev, Dauren
Qin, Gangjian
Misener, Sol
Mackie, Alexander Roy
Kishore, Raj
Volpert, Olga V.
Therapeutic manipulation of angiogenesis with miR-27b
title Therapeutic manipulation of angiogenesis with miR-27b
title_full Therapeutic manipulation of angiogenesis with miR-27b
title_fullStr Therapeutic manipulation of angiogenesis with miR-27b
title_full_unstemmed Therapeutic manipulation of angiogenesis with miR-27b
title_short Therapeutic manipulation of angiogenesis with miR-27b
title_sort therapeutic manipulation of angiogenesis with mir-27b
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497374/
https://www.ncbi.nlm.nih.gov/pubmed/26161255
http://dx.doi.org/10.1186/s13221-015-0031-1
work_keys_str_mv AT veliceasadorina therapeuticmanipulationofangiogenesiswithmir27b
AT biyashevdauren therapeuticmanipulationofangiogenesiswithmir27b
AT qingangjian therapeuticmanipulationofangiogenesiswithmir27b
AT misenersol therapeuticmanipulationofangiogenesiswithmir27b
AT mackiealexanderroy therapeuticmanipulationofangiogenesiswithmir27b
AT kishoreraj therapeuticmanipulationofangiogenesiswithmir27b
AT volpertolgav therapeuticmanipulationofangiogenesiswithmir27b